Table of Content

1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 MARKET SCOPE 20
1.3.1 MARKETS COVERED 20
1.3.2 YEARS CONSIDERED FOR THE STUDY 20
1.4 CURRENCY USED FOR THE STUDY 21
1.5 MAJOR MARKET STAKEHOLDERS 21
1.6 SUMMARY OF CHANGES 21

2 RESEARCH METHODOLOGY 23
2.1 RESEARCH DATA 23
FIGURE 1 RESEARCH DESIGN 23
2.1.1 SECONDARY DATA 24
2.1.1.1 Secondary sources 25
2.1.2 PRIMARY DATA 25
FIGURE 2 BREAKDOWN OF PRIMARIES: CLINICAL TRIAL MANAGEMENT SYSTEM MARKET 26
2.2 MARKET ESTIMATION METHODOLOGY 26
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 27
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 27
2.2.2 END USER-BASED MARKET ESTIMATION 28
FIGURE 4 MARKET SIZE ESTIMATION: CLINICAL TRIAL MANAGEMENT SYSTEM MARKET 28
2.2.3 PRIMARY RESEARCH VALIDATION 28
2.3 DATA TRIANGULATION 29
FIGURE 5 DATA TRIANGULATION METHODOLOGY 29
2.4 RESEARCH ASSUMPTIONS 30
2.5 RESEARCH LIMITATIONS 30

3 EXECUTIVE SUMMARY 31
FIGURE 6 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY PRODUCT AND SERVICE, 2020 VS. 2025 (USD MILLION) 31
FIGURE 7 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY DEPLOYMENT MODE, 2020 VS. 2025 (USD MILLION) 32
FIGURE 8 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY DELIVERY MODE,
2020 VS. 2025 (USD MILLION) 32
FIGURE 9 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY END USER,
2020 VS. 2025 (USD MILLION) 33
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE CLINICAL TRIAL MANAGEMENT SYSTEM MARKET 34

4 PREMIUM INSIGHTS 35
4.1 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET OVERVIEW 35
FIGURE 11 INCREASING RESEARCH PARTNERSHIPS AND OUTSOURCING ARE DRIVING GROWTH IN THE CTMS MARKET 35
4.2 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY DEPLOYMENT MODE 36
FIGURE 12 ENTERPRISE-WIDE DEPLOYMENT DOMINATES THE MARKET 36
4.3 ASIA PACIFIC CLINICAL TRIAL MANAGEMENT SYSTEM MARKET 36
FIGURE 13 LARGE PHARMA-BIOTECH COMPANIES FORM THE LARGEST END-USER SEGMENT IN THE ASIA PACIFIC MARKET 36
4.4 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY REGION 37
FIGURE 14 APAC TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2020–2025) 37

5 MARKET OVERVIEW 38
5.1 INTRODUCTION 38
5.2 MARKET DYNAMICS 38
FIGURE 15 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 38
5.2.1 DRIVERS 39
5.2.1.1 Significant operational costs and regulatory requirements associated with clinical research 39
5.2.1.2 Research partnerships between pharma-biopharma companies and CROs 39
5.2.1.3 The rising number of clinical trials and the availability of advanced CTMS solutions 39
5.2.1.4 Expansion of the target customer base 40
5.2.1.5 Rising government funding and grants to support clinical trials 40
5.2.2 RESTRAINTS 41
5.2.2.1 Budget constraints 41
5.2.3 OPPORTUNITIES 41
5.2.3.1 Increasing outsourcing of research processes 41
5.2.3.2 Greater integration with Platform-as-a-service (PaaS) and mobile computing 42
5.2.3.3 Investment in effective digital infrastructure and agility in technological adoption 42
5.2.4 CHALLENGES 42
5.2.4.1 Lack of skilled professionals 42
5.2.4.2 Fragmented and highly regulated industry 42
5.2.4.3 Patient privacy 43
5.2.4.4 Limited awareness among researchers about associated advantages 43
5.2.5 KEY TRENDS 43
5.2.5.1 Integration of CTMS with software such as HIS, EMR, and EDC 43
5.2.5.2 Mergers and acquisitions 43
5.2.5.3 Shift from manual data interpretation to real-time data analysis during clinical studies 44
5.3 IMPACT OF COVID-19 ON THE CLINICAL TRIAL MANAGEMENT SYSTEM MARKET 44
5.4 ECOSYSTEM COVERAGE: PARENT MARKET (HEALTHCARE IT SOLUTIONS) 45
5.4.1 ECOSYSTEM COVERAGE: CTMS MARKET 45
5.5 MAJOR USE CASES: PARENT MARKET (LIFE SCIENCE ANALYTICS SOLUTIONS) 46

6 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY DEPLOYMENT TYPE 47
6.1 INTRODUCTION 48
TABLE 1 CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION) 48
6.2 ENTERPRISE-WIDE CTMS 48
6.2.1 ENTERPRISE-WIDE CTMS IS PREFERRED BY END USERS 48
TABLE 2 ENTERPRISE-WIDE CTMS MARKET, BY REGION, 2018–2025 (USD MILLION) 48
6.3 ON-SITE CTMS 49
6.3.1 ON-SITE CTMS SUPPORTS IMPROVED CLINICAL TRAILS 49
TABLE 3 ON-SITE CTMS MARKET, BY REGION, 2018–2025 (USD MILLION) 49

7 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY DELIVERY MODE 50
7.1 INTRODUCTION 51
TABLE 4 CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 51
7.2 WEB-BASED (ON-DEMAND) CTMS 51
7.2.1 PROVISION OF CENTRALIZED MANAGEMENT IN CLINICAL TRIALS TO AID THE ADOPTION OF WEB-BASED CTMS 51
TABLE 5 WEB-BASED (ON-DEMAND) CTMS MARKET, BY REGION,
2018–2025 (USD MILLION) 52
7.3 LICENSED ENTERPRISE (ON-PREMISES) CTMS 52
7.3.1 MINIMIZED RISK OF DATA BREACHES AND EXTERNAL ATTACKS SUPPORTS THE USE OF ON-PREMISES CTMS MODELS 52
TABLE 6 LICENSED ENTERPRISE (ON-PREMISES) CTMS MARKET, BY REGION,
2018–2025 (USD MILLION) 53
7.4 CLOUD-BASED (SAAS) 53
7.4.1 HIGH ADAPTABILITY AND RELIABILITY TO AID ADOPTION OF CLOUD-BASED SOLUTIONS 53
TABLE 7 CLOUD-BASED (SAAS) CTMS MARKET, BY REGION,
2018–2025 (USD MILLION) 54

8 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY PRODUCT & SERVICE 55
8.1 INTRODUCTION 56
TABLE 8 CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION) 56
8.2 SOFTWARE 56
8.2.1 RISING NUMBER OF CLINICAL TRIALS TO SUPPORT MARKET GROWTH 56
TABLE 9 CTMS MARKET FOR SOFTWARE, BY REGION, 2018–2025 (USD MILLION) 56
8.3 SERVICES 57
8.3.1 NEED FOR CONTINUOUS UPGRADATION OF CTMS SOFTWARE HAS INCREASED THE DEMAND FOR SERVICES 57
TABLE 10 CTMS MARKET FOR SERVICES, BY REGION, 2018–2025 (USD MILLION) 57

9 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY END USER 58
9.1 INTRODUCTION 59
TABLE 11 CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 59
9.2 LARGE PHARMA-BIOTECH COMPANIES 59
9.2.1 LARGE PHARMA-BIOTECH COMPANIES DOMINATE THE END-USER MARKET 59
FIGURE 16 ACTIVE PHARMACEUTICAL PIPELINE, 2009–2019 60
TABLE 12 CTMS MARKET FOR LARGE PHARMA-BIOTECH COMPANIES, BY REGION, 2018–2025 (USD MILLION) 60
9.3 CONTRACT RESEARCH ORGANIZATIONS 61
9.3.1 RISING OUTSOURCING AND GROWING CRO PRESENCE
ARE KEY GROWTH DRIVERS 61
TABLE 13 CTMS MARKET FOR CROS, BY REGION, 2018–2025 (USD MILLION) 61
9.4 MEDICAL DEVICE MANUFACTURERS 61
9.4.1 NEED TO COMPLY WITH REGULATIONS AND ENSURE PRODUCT SAFETY AND QUALITY HAVE SUPPORTED USE OF CTMS 61
FIGURE 17 R&D SPENDING OF LEADING MEDICAL DEVICE COMPANIES (2018) 62
TABLE 14 CTMS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION,
2018–2025 (USD MILLION) 62
9.5 SMALL & MID-SIZED PHARMA-BIOTECH COMPANIES 63
9.5.1 RISE IN OUTSOURCING TO SMALLER PHARMA COMPANIES IS A KEY DRIVER OF MARKET GROWTH 63
TABLE 15 CTMS MARKET FOR SMALL & MID-SIZED PHARMA-BIOTECH COMPANIES,
BY REGION, 2018–2025 (USD MILLION) 63
9.6 OTHER END USERS 63
TABLE 16 CTMS MARKET FOR OTHER END USERS, BY REGION,
2018–2025 (USD MILLION) 64
10 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET, BY REGION 65
10.1 INTRODUCTION 66
TABLE 17 CTMS MARKET, BY REGION, 2018–2025 (USD MILLION) 66
10.2 NORTH AMERICA 66
FIGURE 18 NORTH AMERICA: CTMS MARKET SNAPSHOT 67
TABLE 18 NORTH AMERICA: CTMS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 67
TABLE 19 NORTH AMERICA: CTMS MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 68
TABLE 20 NORTH AMERICA: CTMS MARKET, BY DEPLOYMENT MODE,
2018–2025 (USD MILLION) 68
TABLE 21 NORTH AMERICA: CTMS MARKET, BY DELIVERY MODE,
2018–2025 (USD MILLION) 68
TABLE 22 NORTH AMERICA: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 69
10.2.1 US 69
10.2.1.1 The US holds the largest share of the North American market 69
TABLE 23 NUMBER OF CLINICAL TRIALS STARTED IN THE US, BY COMPANY, 2017 70
TABLE 24 US: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION) 70
TABLE 25 US: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION) 70
TABLE 26 US: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 71
TABLE 27 US: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 71
10.2.2 CANADA 71
10.2.2.1 Preference of pharmaceutical companies to conduct clinical trials in Canada to support market growth 71
TABLE 28 CANADA: CTMS MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 72
TABLE 29 CANADA: CTMS MARKET, BY DEPLOYMENT MODE,
2018–2025 (USD MILLION) 72
TABLE 30 CANADA: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 72
TABLE 31 CANADA: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 73
10.3 EUROPE 73
TABLE 32 EUROPE: CTMS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 74
TABLE 33 EUROPE: CTMS MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 74
TABLE 34 EUROPE: CTMS MARKET, BY DEPLOYMENT MODE,
2018–2025 (USD MILLION) 74
TABLE 35 EUROPE: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 75
TABLE 36 EUROPE: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 75
10.3.1 GERMANY 75
10.3.1.1 High investments and initiatives in Germany to boost market growth 75
TABLE 37 GERMANY: CTMS MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 76
TABLE 38 GERMANY: CTMS MARKET, BY DEPLOYMENT MODE,
2018–2025 (USD MILLION) 76
TABLE 39 GERMANY: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 76
TABLE 40 GERMANY: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 77
10.3.2 UK 77
10.3.2.1 Favorable R&D scenario in the country to boost software adoption 77
TABLE 41 UK: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION) 77
TABLE 42 UK: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION) 78
TABLE 43 UK: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 78
TABLE 44 UK: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 78
10.3.3 FRANCE 79
10.3.3.1 High number of oncology clinical trials in France to drive market growth 79
TABLE 45 FRANCE: CTMS MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 79
TABLE 46 FRANCE: CTMS MARKET, BY DEPLOYMENT MODE,
2018–2025 (USD MILLION) 79
TABLE 47 FRANCE: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 80
TABLE 48 FRANCE: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 80
10.3.4 ITALY 80
10.3.4.1 Low drug approval times have driven the adoption of CTMS, supporting market growth 80
TABLE 49 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY, 2017 81
TABLE 50 ITALY: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION) 81
TABLE 51 ITALY: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION) 81
TABLE 52 ITALY: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 82
TABLE 53 ITALY: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 82
10.3.5 SPAIN 82
10.3.5.1 Rising R&D expenditure to propel the growth of the Spanish market 82
TABLE 54 SPAIN: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION) 83
TABLE 55 SPAIN: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION) 83
TABLE 56 SPAIN: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 83
TABLE 57 SPAIN: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 84
10.3.6 REST OF EUROPE 84
TABLE 58 ROE: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION) 85
TABLE 59 ROE: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION) 85
TABLE 60 ROE: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 85
TABLE 61 ROE: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 86
10.4 ASIA PACIFIC 86
FIGURE 19 APAC: CLINICAL TRIAL MANAGEMENT SYSTEM MARKET SNAPSHOT 87
TABLE 62 ASIA PACIFIC: CTMS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 87
TABLE 63 ASIA PACIFIC: CTMS MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 88
TABLE 64 ASIA PACIFIC: CTMS MARKET, BY DEPLOYMENT MODE,
2018–2025 (USD MILLION) 88
TABLE 65 ASIA PACIFIC: CTMS MARKET, BY DELIVERY MODE,
2018–2025 (USD MILLION) 88
TABLE 66 ASIA PACIFIC: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 89
10.4.1 CHINA 89
10.4.1.1 Low cost of clinical trials and large pharmaceutical R&D base in China to drive market growth 89
TABLE 67 CHINA: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION) 90
TABLE 68 CHINA: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION) 90
TABLE 69 CHINA: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 90
TABLE 70 CHINA: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 91
10.4.2 JAPAN 91
10.4.2.1 Stringent regulatory scenario in Japan to restrain the market growth 91
TABLE 71 JAPAN: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION) 91
TABLE 72 JAPAN: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION) 92
TABLE 73 JAPAN: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 92
TABLE 74 JAPAN: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 92
10.4.3 INDIA 93
10.4.3.1 Favorable pharmaceutical R&D scenario to drive software adoption 93
TABLE 75 INDIA: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION) 93
TABLE 76 INDIA: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION) 93
TABLE 77 INDIA: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 94
TABLE 78 INDIA: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 94
10.4.4 AUSTRALIA 94
10.4.4.1 Government support for clinical trials to boost the market in Australia 94
TABLE 79 AUSTRALIA: CTMS MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 94
TABLE 80 AUSTRALIA: CTMS MARKET, BY DEPLOYMENT MODE,
2018–2025 (USD MILLION) 95
TABLE 81 AUSTRALIA: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 95
TABLE 82 AUSTRALIA: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 95
10.4.5 SOUTH KOREA 96
10.4.5.1 Growth of the contract research sector indicates opportunities for CTMS providers 96
TABLE 83 SOUTH KOREA: CTMS MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 96
TABLE 84 SOUTH KOREA: CTMS MARKET, BY DEPLOYMENT MODE,
2018–2025 (USD MILLION) 96
TABLE 85 SOUTH KOREA: CTMS MARKET, BY DELIVERY MODE,
2018–2025 (USD MILLION) 96
TABLE 86 SOUTH KOREA: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 97
10.4.6 REST OF ASIA PACIFIC 97
TABLE 87 ROAPAC: CTMS MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 97
TABLE 88 ROAPAC: CTMS MARKET, BY DEPLOYMENT MODE,
2018–2025 (USD MILLION) 97
TABLE 89 ROAPAC: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 98
TABLE 90 ROAPAC: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 98
10.5 LATIN AMERICA 98
10.5.1 RISING INVESTMENTS AND HEALTHCARE EXPENDITURE SHOW POTENTIAL FOR MARKET GROWTH 98
TABLE 91 LATAM: CTMS MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 99
TABLE 92 LATAM: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION) 99
TABLE 93 LATAM: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 99
TABLE 94 LATAM: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 100
10.6 MIDDLE EAST AND AFRICA 100
10.6.1 GROWING AVAILABILITY OF FUNDING IN THE MIDDLE EAST INDICATES OPPORTUNITIES FOR MARKET GROWTH 100
TABLE 95 MEA: CTMS MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION) 101
TABLE 96 MEA: CTMS MARKET, BY DEPLOYMENT MODE, 2018–2025 (USD MILLION) 101
TABLE 97 MEA: CTMS MARKET, BY DELIVERY MODE, 2018–2025 (USD MILLION) 101
TABLE 98 MEA: CTMS MARKET, BY END USER, 2018–2025 (USD MILLION) 102
?

11 COMPETITIVE LANDSCAPE 103
11.1 OVERVIEW 103
FIGURE 20 KEY DEVELOPMENTS IN THE CLINICAL TRIAL MANAGEMENT SYSTEM MARKET (2017–2020) 103
11.2 GLOBAL CLINICAL TRIAL MANAGEMENT SYSTEM MARKET SHARE ANALYSIS (2019) 104
FIGURE 21 ORACLE HELD THE LEADING POSITION IN THE CLINICAL TRIAL MANAGEMENT SYSTEM MARKET IN 2019 104
11.3 COMPETITIVE SCENARIO (2017–2020) 105
11.3.1 KEY PRODUCT LAUNCHES AND PRODUCT DEPLOYMENTS (2017–2020) 105
11.3.2 KEY EXPANSIONS (2017–2020) 105
11.3.3 KEY MERGERS, DIVESTITURES, AND ACQUISITIONS (2017–2020) 106
11.3.4 KEY AGREEMENTS, CONTRACTS, AND PARTNERSHIPS (2017–2020) 106
11.4 COMPETITIVE LEADERSHIP MAPPING 107
11.5 VENDOR INCLUSION CRITERIA 107
11.5.1 STARS 107
11.5.2 EMERGING LEADERS 107
11.5.3 PERVASIVE PLAYERS 107
11.5.4 PARTICIPANTS 108
FIGURE 22 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET: GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2019 108
11.6 COMPETITIVE LEADERSHIP MAPPING: EMERGING COMPANIES/SMES/
START-UPS (2019) 109
11.6.1 PROGRESSIVE COMPANIES 109
11.6.2 STARTING BLOCKS 109
11.6.3 RESPONSIVE COMPANIES 109
11.6.4 DYNAMIC COMPANIES 109
FIGURE 23 CLINICAL TRIAL MANAGEMENT SYSTEM MARKET: GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2019 (SMES/START-UPS) 110
12 COMPANY PROFILES 111
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 ORACLE 111
FIGURE 24 ORACLE: COMPANY SNAPSHOT 111
12.2 MEDIDATA SOLUTIONS 113
FIGURE 25 MEDIDATA SOLUTIONS: COMPANY SNAPSHOT 113
12.3 PAREXEL INTERNATIONAL CORPORATION 117
12.4 IBM 119
FIGURE 26 IBM: COMPANY SNAPSHOT 119
12.5 BIOCLINICA 121
12.6 BIO-OPTRONICS 123
12.7 DATATRAK INTERNATIONAL 125
FIGURE 27 DATATRAK INTERNATIONAL: COMPANY SNAPSHOT 125
?
12.8 VEEVA SYSTEMS 127
FIGURE 28 VEEVA SYSTEMS: COMPANY SNAPSHOT 127
12.9 MASTERCONTROL 129
12.10 DSG 130
12.11 ERT 131
12.12 ADVARRA TECHNOLOGY SOLUTIONS 133
12.13 MEDNET SOLUTIONS 134
12.14 ARISGLOBAL 136
12.15 DZS CLINICAL SERVICES (WDB HOLDINGS CO. LTD) 137
12.16 EMERGING PLAYERS/START-UPS 138
12.16.1 CRUCIAL DATA SOLUTIONS (CDS) 138
12.16.2 ENNOV 138
12.16.3 DATASTAT 139
12.16.4 BSI 139
12.16.5 REALTIME SOFTWARE SOLUTIONS LLC 140
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13 APPENDIX 141
13.1 RESEARCH DATA 141
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 146
13.3 AVAILABLE CUSTOMIZATIONS 148
13.4 RELATED REPORTS 148
13.5 AUTHOR DETAILS 150